Edwards Lifesciences Statistics
Edwards Lifesciences (0REN) Stock Statistics & Valuation Metrics
Total Valuation
Edwards Lifesciences has a market cap or net worth of CHF 51.70B. The enterprise value is CHF 46.02B.
- Market Cap
- CHF 51.70B
- Enterprise Value
- CHF 46.02B
Share Statistics
Edwards Lifesciences has 575,000,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 575,000,000
- Owned by Insiders
- 0.20%
- Owned by Institutions
- 74.78%
Financial Efficiency
Edwards Lifesciences’s return on equity (ROE) is 0.10 and return on invested capital (ROIC) is 11.40%.
- Return on Equity (ROE)
- 0.10
- Return on Assets (ROA)
- 0.08
- Return on Invested Capital (ROIC)
- 11.40%
- Return on Capital Employed (ROCE)
- 0.14
- Revenue Per Employee
- 379.23K
- Profits Per Employee
- 67.09K
- Employee Count
- 16,000
- Asset Turnover
- 0.44
- Inventory Turnover
- 1.18
Valuation Ratios
The current PE Ratio of Edwards Lifesciences is 60.54. Edwards Lifesciences’s PEG ratio is -2.52.
- PE Ratio
- 60.54
- PS Ratio
- 9.23
- PB Ratio
- 5.69
- Price to FCF
- 43.26
- Price to Operating Cash Flow
- 35.97
- PEG Ratio
- -2.52
Income Statement
In the last 12 months, Edwards Lifesciences had revenue of 6.07B and earned 1.07B in profits. Earnings per share was 1.84.
- Revenue
- 6.07B
- Gross Profit
- 4.74B
- Operating Income
- 1.64B
- Pretax Income
- 1.27B
- Net Income
- 1.07B
- EBITDA
- 1.43B
- Earnings Per Share (EPS)
- 1.84
Cash Flow
In the last 12 months, operating cash flow was 1.72B and capital expenditures -292.80M, giving a free cash flow of 1.42B billion.
- Operating Cash Flow
- 1.72B
- Free Cash Flow
- 1.42B
- Free Cash Flow per Share
- 2.47
Dividends & Yields
Edwards Lifesciences pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 2.31%
- Earnings Yield
- 1.65%
Important Dates
Edwards Lifesciences upcoming earnings date is Jan 27, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 04, 2026
- Next Earnings Date
- Jan 27, 2027
- Ex-Dividend Date
- ―
Financial Position
Edwards Lifesciences as a current ratio of 3.72, with Debt / Equity ratio of 6.82%
- Current Ratio
- 3.72
- Quick Ratio
- 3.09
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- -1.56
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Edwards Lifesciences has paid 216.90M in taxes.
- Income Tax
- 216.90M
- Effective Tax Rate
- 0.17
Enterprise Valuation
Edwards Lifesciences EV to EBITDA ratio is 36.93, with an EV/FCF ratio of 41.57.
- EV to Sales
- 8.87
- EV to EBITDA
- 36.93
- EV to Free Cash Flow
- 41.57
- EV to Operating Cash Flow
- 34.48
Balance Sheet
Edwards Lifesciences has CHF 4.64B in cash and marketable securities with CHF 704.50M in debt, giving a net cash position of CHF 3.94B billion.
- Cash & Marketable Securities
- CHF 4.64B
- Total Debt
- CHF 704.50M
- Net Cash
- CHF 3.94B
- Net Cash Per Share
- CHF 6.85
- Tangible Book Value Per Share
- CHF 13.62
Margins
Gross margin is 78.13%, with operating margin of 25.52%, and net profit margin of 15.30%.
- Gross Margin
- 78.13%
- Operating Margin
- 25.52%
- Pretax Margin
- 21.46%
- Net Profit Margin
- 15.30%
- EBITDA Margin
- 24.02%
- EBIT Margin
- 21.46%
Analyst Forecast
The average price target for Edwards Lifesciences is CHF 96.42, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- CHF 96.42
- Price Target Upside
- ―
- Analyst Consensus
- Strong Buy
- Analyst Count
- 23
- Revenue Growth Forecast
- 6.41%
- EPS Growth Forecast
- -31.90%
Scores
- Smart Score
- 8
- AI Score
- ―

